Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Surrozen, Inc. (SRZN : NSDQ)

• Company Description    Surrozen Inc. is a company pioneering targeted therapeutics which selectively activates the Wnt pathway for tissue repair and regeneration. Surrozen Inc., formerly known as Consonance-HFW Acquisition Corp., is based in SOUTH SAN FRANCISCO, Calif. Number of Employees: 41

• Price / Volume Information    Yesterday's Closing Price: $11.57 Daily Weekly Monthly 20 Day Moving Average: 12,144 shares Shares Outstanding: 8.57 (millions) Market Capitalization: $99.12 (millions) Beta: 0.62 52 Week High: $18.17 52 Week Low: $5.90 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 6.60% 4.72% 12 Week 16.83% 6.12% Year To Date -19.40% -29.01%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 171 Oyster Point Blvd Suite 400 - South San Francisco,CA 94080 USA ph: 650-489-9000 fax: - investorinfo@surrozen.com http://www.surrozen.com

• General Corporate Information    Officers Craig Parker - President and Chief Executive Officer and Director David J. Woodhouse - Chair of the Board of Directors Charles Williams - Chief Financial Officer and Chief Operating Office Anna Berkenblit - Director Christopher Chai - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 86889P208 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/05/25 Share - Related Items Shares Outstanding: 8.57 Most Recent Split Date: 12.00 (0.07:1) Beta: 0.62 Market Capitalization: $99.12 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.17 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.83 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.10 Price/Cash Flow: - Price / Sales: 7.85 EPS Growth vs. Year Ago Period: 25.97% vs. Previous Quarter: 63.58% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: 0.00% ROE 06/30/25 - -545.43 03/31/25 - - 12/31/24 - -842.90 ROA 06/30/25 - -64.40 03/31/25 - -71.32 12/31/24 - -96.87 Current Ratio 06/30/25 - 16.41 03/31/25 - 10.02 12/31/24 - 5.32 Quick Ratio 06/30/25 - 16.41 03/31/25 - 10.02 12/31/24 - 5.32 Operating Margin 06/30/25 - -400.56 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - -274.42 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - -132.29 03/31/25 - -702.04 12/31/24 - -596.57 Book Value 06/30/25 - 5.50 03/31/25 - 0.67 12/31/24 - -6.55 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - - Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - -

Powered by Zacks Investment Research ©